Enliven Therapeutics, Inc. (ELVN) Stock Analysis
Healthcare · Biotechnology
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical... Read more
TrendMatrix rates Enliven Therapeutics, Inc. (ELVN) as Sell with moderate confidence. The stock trades at $35.58 with +1.0% upside to the $36.00 price target. Overall score: 4.6/10 across 10 analysis dimensions. Reward/risk ratio: 0.0:1.
Passes 3/4 gates (positive momentum, clean insider activity, no SEC red flags). Fails on favorable risk/reward ratio. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Enliven Therapeutics, Inc. (ELVN) as Sell with moderate confidence. Score 4.6/10.
Take-profit target: $36.00 (+1.0% upside). Reward/risk ratio: 0.0:1. Stop-loss: $25.90.
V8: Target reached (-1.6% upside); Quality below floor (1.8 < 4.0).
Enliven Therapeutics, Inc. trades at a P/E of N/A (forward -9.2). TrendMatrix value score: 4.0/10. Verdict: Sell.
16 analysts cover ELVN with a consensus score of 4.3/5. Average price target: $41.
What does Enliven Therapeutics, Inc. do?Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of...
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.